Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

16.46 -0.52 (-3.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,296,432
Open 16.94
Bid (Size) 16.30 (1)
Ask (Size) 16.50 (3)
Prev. Close 16.98
Today's Range 16.19 - 17.09
52wk Range 5.240 - 18.39
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga

Performance

YTD
+137.86%
+137.86%
1 Month
+9.37%
+9.37%
3 Month
+19.54%
+19.54%
6 Month
+134.47%
+134.47%
1 Year
+137.52%
+137.52%

More News

Read More
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Via MarketBeat
Catalyst Pharma, The No. 1 IBD 50 Stock, Just Trounced Third-Quarter Expectations
Via Investor's Business Daily
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
Via MarketBeat
Topics ETFs Initial Public Offering
Exposures Securities Market
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
These 3 Stocks Are Winning the Bear Market -- Here's How
Via The Motley Fool
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Via MarketBeat
Topics Stocks
Exposures US Equities
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
Via Investor's Business Daily
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
Via Investor's Business Daily
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
Via Investor's Business Daily
FedEx, UPS And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Nikola, Bed Bath & Beyond And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Why Catalyst Pharmaceuticals Shares Are Popping Off
Via Benzinga
Planet Labs, Core & Main And Some Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.